Literature DB >> 12692269

Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.

Jenny C Luxton1, Rahul Nath2, Nawal Derias3, Amanda Herbert3, Philip S Shepherd1.   

Abstract

Human papillomavirus type 16 (HPV-16) L1- and E7-specific T cell responses were measured in 58 women with abnormal cervical cytology in a prospective study. On recruitment, patients responded most frequently and with the highest numbers of responding cells to the L1 region aa 311-345 and this response was significantly associated with the presence of cervical disease (P=0.041). Responses to the L1 peptide aa 281-295 were significantly higher in patients with CIN III than in those with HPV/CIN I or CIN II lesions (P=0.027). The E7 region aa 70-98 was the most immunogenic in patients with squamous intraepithelial lesions of the cervix (SIL) but the responses detected were not significantly higher than in patients without SIL. Following treatment, the T cell response profiles of patient groups did not change significantly. However, on analysis of the responses of individual patients with and without recurrent disease on follow-up, significant differences were found. Recurrence of disease was associated with T cell responses to the E7 region aa 70-98 at the patient's first clinic visit (P=0.017). Recurrence of disease was also accompanied by an increase in the total number of L1-specific short-term T cell lines (STLs) at follow-up, whereas absence of disease was accompanied by a decrease in L1-specific STLs. The data also suggested a possible link between E7 70-98-specific responses and acquisition of disease by patients who were previously disease-free. Further studies are warranted to determine whether this response could be useful as a marker of recurrent disease in some patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692269     DOI: 10.1099/vir.0.18931-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  4 in total

1.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

2.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

3.  Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.

Authors:  Félix Giovanni Delgado; Elizabeth Martínez; María Angélica Céspedes; María Mercedes Bravo; María Cristina Navas; Alba Lucía Cómbita Rojas
Journal:  Immunology       Date:  2008-09-05       Impact factor: 7.397

4.  Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.

Authors:  J Visser; H W Nijman; B-N Hoogenboom; P Jager; D van Baarle; E Schuuring; W Abdulahad; F Miedema; A G van der Zee; T Daemen
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.